SCHEMBL30296265

SCHEMBL30296265

C=CCC[C@@H](Nc1ccc(OC)cc1)c1nccc(F)c1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
MAPK1 P28482 3/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
AURKA O14965 2/20 0.35
SYK P43405 1/20 0.35
ALDH1A1 P00352 7/20 0.35
HTT P42858 2/20 0.35
CYP3A4 P08684 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
GAA P10253 2/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296267 0.84 MAPT (0.34) MAPTMEN1KMT2AL3MBTL1MAPK1
SCHEMBL30296536 0.82 L3MBTL1 (0.38) MAPTMEN1KMT2AL3MBTL1MAPK1
SCHEMBL30296323 0.82 L3MBTL1 (0.38) MAPTMEN1KMT2AL3MBTL1MAPK1
SCHEMBL30391197 0.82 L3MBTL1 (0.40) MAPTMEN1KMT2AL3MBTL1MAPK1
SCHEMBL26880317 0.82 L3MBTL1 (0.40) MAPTMEN1KMT2AL3MBTL1MAPK1
SCHEMBL30296529 0.81 MEN1 (0.39) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL30391023 0.80 MEN1 (0.36) MAPTMEN1KMT2AL3MBTL1MAPK1
SCHEMBL30296352 0.78 MEN1 (0.35) MAPTMEN1KMT2AL3MBTL1MAPK1
SCHEMBL24571164 0.78 MAPT (0.36) MAPTMEN1KMT2AL3MBTL1MAPK1
SCHEMBL29073836 0.78 MEN1 (0.36) MAPTMEN1KMT2AL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 MAPT 4580/4885MEN1 4599/4885KMT2A 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.